Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver.

The study is being led by Rebecca Auer, M.D., surgical oncologist at The Ottawa Hospital, associate scientist at the Ottawa Hospital Research Institute and assistant professor of surgery at the University of Ottawa in Ottawa, Canada.  The clinical trial is being supported by funding from the Ontario Institute for Cancer Research­.

"This trial will allow us to evaluate the use of JX-594 in patients with surgically resectable disease, potentially expanding the role of this therapy in the treatment continuum," said David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We continue to believe that JX-594 could play an integral role in the treatment of cancers and look forward to the results of this trial along with data from the larger Phase 2b study, called TRAVERSE, that is under way in patients with advanced hepatocellular carcinoma."

"In addition, this study will allow us to expand our analysis of the multi-mechanistic therapeutic activity of JX-594 through the examination of tumor specimens collected during surgery following JX-594 administration," said John C. Bell, Ph.D., senior scientist, cancer therapeutics, Ottawa Hospital Research Institute, and professor of medicine, University of Ottawa.  Dr. Bell is also the program leader of the Ontario Institute for Cancer Research's Immuno- and Bio-therapies Program.

This Phase 2a clinical trial will enroll approximately 20 patients with colorectal cancer metastases to the liver. Patients will receive a single
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 Alvarado ... 23, called the Alvarado Spine & Joint Institute. ... and rehabilitation, focusing on spinal surgery and joint ... patient care takes a patient experience-focused approach. For ... they feel comfortable in, rather than patient gowns. ...
(Date:7/29/2015)... , July 29, 2015 ... Devices Market by Product, Diagnostic (PSG, Pulse Oximeter), Therapeutic ... (Mandibular Advancement Device)], End User (Home Care Settings, Hospitals) ... MarketsandMarkets, this report studies the global Sleep Apnea Devices ... This market is expected to reach $5.3 Billion by ...
(Date:7/29/2015)... 29, 2015   KaloBios Pharmaceuticals, Inc . (Nasdaq: ... developing innovative therapies to benefit patients with diseases of ... today that the U.S. Food and Drug Administration (FDA) ... for KB003, an anti-GM-CSF monoclonal antibody (mAb), in patients ... is now active. The acceptance of this ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Sleep Apnea Devices Market Worth $5.3 Billion by 2020 2Sleep Apnea Devices Market Worth $5.3 Billion by 2020 3Sleep Apnea Devices Market Worth $5.3 Billion by 2020 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5
... U.S. announced that the U.S. Food and Drug Administration ... be used for the initial management of plasma uric ... and solid tumor malignancies who are receiving anti-cancer therapy ... subsequent elevations of plasma uric acid. ...
... Balch Hill Medical, Inc. of Hanover, New Hampshire, ... Catheter System, which is designed to increase the rate ... the company, which grew out of the Dartmouth Medical ... design dramatically reduces the two main causes of IV ...
Cached Medicine Technology:FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 2FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 3FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 4FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 5FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 6FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy 7Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent 2Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent 3
(Date:7/29/2015)... Garden City, NY (PRWEB) , ... July 30, ... ... (NAPW) honors Laura Ballard, M.S., MSTi, as a 2015-2016 inductee ... with this prestigious distinction for leadership in mental health counseling. With more than ...
(Date:7/29/2015)... Mary, FL (PRWEB) , ... July 29, 2015 , ... ... Healthcare Providers and Systems (CAHPS) for PQRS Survey. , The CAHPS for PQRS ... In 2015, practices of 100 or more eligible providers must participate or they will ...
(Date:7/29/2015)... ... ... Conventional theories used by economists for the past 150 years to explain how ... about the behavior of microbial life on earth, according to a study by researchers ... published July 29 in the open access journal PLOS ONE, provide new insight into ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... president within Abt’s U.S. Health division. In her position, Ramkeesoon will help ... Prior to joining Abt, Ramkeesoon spent close to a decade at ICF International, ...
(Date:7/29/2015)... D.C. (PRWEB) , ... July 29, 2015 , ... ... released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older ... in seniors and offers recommendations on how industry, government, and health care experts ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Laura Ballard, Lead Clinician / Founder, Abundant Transformation / Evergreen Professional Counseling, Into its VIP Woman of the Year Circle 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3Health News:University Researchers Apply Economic Concepts to Explore the Mysteries of the Microbial World 2Health News:University Researchers Apply Economic Concepts to Explore the Mysteries of the Microbial World 3Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3
... 4, 2008 The U.S. Pharmacopeia (USP) today announced ... Chemicals Codex (FCC), a compendium that sets standards for ... foods consumed by the public every day, including colorings, ... new edition is the sixth publication of the compendium ...
... Award and Massachusetts again takes ... top e-Prescribing State Honors, ... the leader in hosted services for email encryption and,e-prescribing, today ... 2008, for building awareness of improving,patient safety at the local ...
... Receives 106 Sleep Number Beds, MINNEAPOLIS, Mar. 4 ... leading bed retailer, is donating,106 SLEEP NUMBER(R) beds plus ... Angeles. Select Comfort will deliver and set-up,the beds on ... receive Select Comfort,s generous gift of Sleep,Number beds," said ...
... . , The doctoral thesis of Isaac Manuel ... Department of Signal Theory, Telematics, and Communication , and Department ... Granada , and directed by Professors ngel de la Torre ... of this work includes improving the acquisition of Compound Action Potential ...
... two closely related strains of the influenza A virus ... epidemics, according to biologists. The findings could help explain ... to seasonal epidemics., Until now, it was believed that while ... influenza viruses that infect birds causes severe pandemics, ...
... 4 BlueCross BlueShield of South,Carolina announced today that ... held during lunchtime hours on Wednesday, April 30, 2008., ... country, as well as,other employers, will encourage their employees ... participate in a 30-minute lunchtime walk., The motivation ...
Cached Medicine News:Health News:US Pharmacopeia releases new edition of the Food Chemicals Codex 2Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 2Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 3Health News:Select Comfort Helps Families Sleep Better in Los Angeles 2Health News:Select Comfort Helps Families Sleep Better in Los Angeles 3Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 3Health News:Study uncovers cause of flu epidemics 2Health News:Study uncovers cause of flu epidemics 3Health News:S.C. BlueCross Announces Second Annual National Walk @ Lunch Day 2
... Primus PDQ Plus for the determination of A1c ... results. The PDQ Plus is a fully automated ... reading for the ultimate in safety and positive ... is well known to be interference-free and to ...
... Testing , Monoclonal antibody method for ... Correlation study shows 99% agreement with the ... count on a CV of 2.6%* ... Glycohemoglobin Standardization Program (NGSP) certified method, as ...
... The intelligent CELL-DYN WorkCell delivers complete hematology ... operator safety. A modular configuration provides the ... basic system includes one Navigator module, one ... main bar code reader. The basic system ...
... Cascade M is a manual hemostasis ... routine clotting assays - PTs, aPTTs, ... for easy, inexpensive, low-volume testing, this ... big on features, offering time and ...
Medicine Products: